arrow
E

Elizabeth A. Thompson

Johns Hopkins University
H指数:33
被引数:8,245

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study

联合使用癌症疫苗、pembrolizumab 和立体定向体部放射治疗局部晚期胰腺癌患者的疗效:一项单臂、II 期研究

2026-03-180
OAAI
Sex differences in B cell dynamics after seasonal influenza vaccination are dependent on the age and hormonal status of vaccinees
2025-11-010
PRE
Immune Response to MVA-BN and Prior Smallpox Vaccination in People With HIV or at Risk for HIV Acquisition

HIV感染者或HIV感染高风险人群对MVA-BN和既往天花疫苗接种的免疫应答

2025-08-140
OAAI
SARS-CoV-2 induces neutrophil degranulation and differentiation into myeloid-derived suppressor cells associated with severe COVID-19

SARS-CoV-2诱导中性粒细胞脱颗粒并分化为髓源性抑制细胞,这与重症COVID-19相关。

2025-05-210
PRE
Distinct myeloid-derived suppressor cell populations in human glioblastoma

人类胶质母细胞瘤中不同的髓源性抑制细胞群

Science
IF45.8
2025-01-010
OAAI
Three doses of COVID-19 mRNA vaccine induce class-switched antibody responses in inflammatory arthritis patients on immunomodulatory therapies
2023-10-240
OAAI
Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses
IMMUNITY
IF26.3
2023-10-0120
OA
Glutamine antagonist prodrug JHU083 reprograms immunosuppressive tumor-associated macrophages to drive tumor immunity in urologic cancers
2023-06-020
PRE
Persistent SARS-CoV-2-specific immune defects in kidney transplant recipients following third mRNA vaccine dose

第三剂mRNA疫苗后肾移植受者的持续性SARS-CoV-2-specific免疫缺陷

2023-06-018
OAAI
Progress in vaccine development for infectious diseases-a Keystone Symposia report

传染病疫苗开发的进展-Keystone专题讨论会报告

2023-04-054
PRE
Glutamine antagonist prodrug JHU083 reprograms immunosuppressive tumor-associated macrophages (TAMs) to drive tumor immunity in urologic cancers
2023-04-041
PRE
Circulating cell-free tumor DNA dynamics capture minimal residual disease with neoadjuvant immune checkpoint blockade plus chemoradiotherapy for patients with operable esophageal/gastroesophageal junction cancer
2023-04-040
PRE
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC
2022-12-0127
OAAI